Dicerna expects to continue collaborating with Novo's rivals after potential acquisition
CEO at Dicerna Douglas Fambrough is fully anticipating that the US-based biotech company will live up to the obligations it has made to other companies, even in the case that the recently announced takeover bid by Novo Nordisk is a success, he tells MedWatch.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY DANIEL PEDERSEN
Even if Novo Nordisk's takeover bid becomes a success, business will continue as usual when it comes to Dicerna's partnerships with Novo's rivals Eli Lilly and Boehringer Ingelheim, CEO at Dicerna Douglas Fambrough tells MedWatch.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk acquires Dicerna for USD 3.3bn
For subscribers
